María Alejandra Gómez-Rocha, Carlos Mario Rangel, Juan David Arias, Alejandro Tello, Virgilio Galvis, Sylvia J Villamizar, Sergio Mancero, Germán Mejía-Salgado
{"title":"哥伦比亚人群中近视黄斑病变的特征及其亚型和视力结果的相关因素","authors":"María Alejandra Gómez-Rocha, Carlos Mario Rangel, Juan David Arias, Alejandro Tello, Virgilio Galvis, Sylvia J Villamizar, Sergio Mancero, Germán Mejía-Salgado","doi":"10.1177/11206721251340431","DOIUrl":null,"url":null,"abstract":"<p><p>PurposeTo evaluate the diagnostic and prognostic utility of the atrophy-traction-neovascularization (ATN) classification in characterizing myopic maculopathy (MM) and identifying factors influencing its subtypes and visual outcomes.Methods228 eyes (136 patients) with high myopia [spherical equivalent (SE) ≤ -6.00 diopters (D) or axial length (AL) ≥ 26.5 mm] were assessed. Ocular evaluations included optical coherence tomography and ocular biometry. MM was classified into three subtypes: myopic atrophy-maculopathy (MAM), myopic tractional-maculopathy (MTM), and myopic neovascular-maculopathy (MNM). Final corrected-distance-visual-acuity (CDVA), AL, and SE were compared between eyes with and without MM and its subtypes. Univariate and multivariate models were used to identify related factors in each subtype: moderate-severe vision impairment (final CDVA between 20/70-20/400) and blindness (final CDVA < 20/400).ResultsMM was present in 58.8% of cases, 52.2% had MAM, 27.2% MNM and 14% MNM. Notably, fifteen eyes (11.2%) exhibited traction or neovascularization without atrophy. Eyes with MM exhibited worse BCVA, more negative SE, and longer AL than those without MM (p < 0.001). AL ≥ 30 mm was related to MAM (OR = 1.51; 95% CI 1.30-3.00; p = 0.004) and MNM (OR = 9.36; 95% CI 1.56-13.08; p = 0.021). Blindness was related to aged ≥ 50 years (OR = 2.80; 95% CI 1.30-6.05; p = 0.010), MTM (OR = 1.90; 95% CI 1.80-4.80; p = 0.029), and MNM (OR = 5.60; 95% CI 2.78-15.55; p = 0.005).ConclusionThe ATN classification is valuable for diagnosing and prognosing MM, as it identifies subtypes and key factors influencing visual outcomes. Notably, tractional and neovascular changes, detected in ATN but often undetectable on fundus photography, were linked to worse visual prognosis, reinforcing its clinical relevance.</p>","PeriodicalId":12000,"journal":{"name":"European Journal of Ophthalmology","volume":" ","pages":"11206721251340431"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Characterization of myopic maculopathy and related factors of its subtypes and visual outcomes in a Colombian population.\",\"authors\":\"María Alejandra Gómez-Rocha, Carlos Mario Rangel, Juan David Arias, Alejandro Tello, Virgilio Galvis, Sylvia J Villamizar, Sergio Mancero, Germán Mejía-Salgado\",\"doi\":\"10.1177/11206721251340431\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>PurposeTo evaluate the diagnostic and prognostic utility of the atrophy-traction-neovascularization (ATN) classification in characterizing myopic maculopathy (MM) and identifying factors influencing its subtypes and visual outcomes.Methods228 eyes (136 patients) with high myopia [spherical equivalent (SE) ≤ -6.00 diopters (D) or axial length (AL) ≥ 26.5 mm] were assessed. Ocular evaluations included optical coherence tomography and ocular biometry. MM was classified into three subtypes: myopic atrophy-maculopathy (MAM), myopic tractional-maculopathy (MTM), and myopic neovascular-maculopathy (MNM). Final corrected-distance-visual-acuity (CDVA), AL, and SE were compared between eyes with and without MM and its subtypes. Univariate and multivariate models were used to identify related factors in each subtype: moderate-severe vision impairment (final CDVA between 20/70-20/400) and blindness (final CDVA < 20/400).ResultsMM was present in 58.8% of cases, 52.2% had MAM, 27.2% MNM and 14% MNM. Notably, fifteen eyes (11.2%) exhibited traction or neovascularization without atrophy. Eyes with MM exhibited worse BCVA, more negative SE, and longer AL than those without MM (p < 0.001). AL ≥ 30 mm was related to MAM (OR = 1.51; 95% CI 1.30-3.00; p = 0.004) and MNM (OR = 9.36; 95% CI 1.56-13.08; p = 0.021). Blindness was related to aged ≥ 50 years (OR = 2.80; 95% CI 1.30-6.05; p = 0.010), MTM (OR = 1.90; 95% CI 1.80-4.80; p = 0.029), and MNM (OR = 5.60; 95% CI 2.78-15.55; p = 0.005).ConclusionThe ATN classification is valuable for diagnosing and prognosing MM, as it identifies subtypes and key factors influencing visual outcomes. Notably, tractional and neovascular changes, detected in ATN but often undetectable on fundus photography, were linked to worse visual prognosis, reinforcing its clinical relevance.</p>\",\"PeriodicalId\":12000,\"journal\":{\"name\":\"European Journal of Ophthalmology\",\"volume\":\" \",\"pages\":\"11206721251340431\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-05-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Ophthalmology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/11206721251340431\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/11206721251340431","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Characterization of myopic maculopathy and related factors of its subtypes and visual outcomes in a Colombian population.
PurposeTo evaluate the diagnostic and prognostic utility of the atrophy-traction-neovascularization (ATN) classification in characterizing myopic maculopathy (MM) and identifying factors influencing its subtypes and visual outcomes.Methods228 eyes (136 patients) with high myopia [spherical equivalent (SE) ≤ -6.00 diopters (D) or axial length (AL) ≥ 26.5 mm] were assessed. Ocular evaluations included optical coherence tomography and ocular biometry. MM was classified into three subtypes: myopic atrophy-maculopathy (MAM), myopic tractional-maculopathy (MTM), and myopic neovascular-maculopathy (MNM). Final corrected-distance-visual-acuity (CDVA), AL, and SE were compared between eyes with and without MM and its subtypes. Univariate and multivariate models were used to identify related factors in each subtype: moderate-severe vision impairment (final CDVA between 20/70-20/400) and blindness (final CDVA < 20/400).ResultsMM was present in 58.8% of cases, 52.2% had MAM, 27.2% MNM and 14% MNM. Notably, fifteen eyes (11.2%) exhibited traction or neovascularization without atrophy. Eyes with MM exhibited worse BCVA, more negative SE, and longer AL than those without MM (p < 0.001). AL ≥ 30 mm was related to MAM (OR = 1.51; 95% CI 1.30-3.00; p = 0.004) and MNM (OR = 9.36; 95% CI 1.56-13.08; p = 0.021). Blindness was related to aged ≥ 50 years (OR = 2.80; 95% CI 1.30-6.05; p = 0.010), MTM (OR = 1.90; 95% CI 1.80-4.80; p = 0.029), and MNM (OR = 5.60; 95% CI 2.78-15.55; p = 0.005).ConclusionThe ATN classification is valuable for diagnosing and prognosing MM, as it identifies subtypes and key factors influencing visual outcomes. Notably, tractional and neovascular changes, detected in ATN but often undetectable on fundus photography, were linked to worse visual prognosis, reinforcing its clinical relevance.
期刊介绍:
The European Journal of Ophthalmology was founded in 1991 and is issued in print bi-monthly. It publishes only peer-reviewed original research reporting clinical observations and laboratory investigations with clinical relevance focusing on new diagnostic and surgical techniques, instrument and therapy updates, results of clinical trials and research findings.